PSEN1 and Alzheimer disease: To further substantiate the rationale that RD2 will show the same efficacy also in AD patients, we demonstrated that the Aβ oligomers obtained from brains of the APP/PS1 mouse model and from human patients do have very similar size distributions, suggesting that the target Aβ oligomer has similar properties in both sources.